Aurizon vs Atlas Arteria shares: Which high-yield ASX 200 stock is better for safe passive income?

Thinking about parking your hard-earned cash in a top-yielding ASX 200 stock for some peace-of-mind passive income? Aurizon Holdings Ltd (ASX: AZJ) and Atlas Arteria Ltd (ASX: ALX) are both popular picks among income-focused investors, and each has its loyal fan base. But when you’re weighing up Aurizon vs Atlas Arteria shares, which one stands out as the better option for those craving a regular, reliable dividend stream? Let’s break down the essentials.

The case for Aurizon

Aurizon is Australia’s largest rail freight operator, moving a hefty volume of commodities—like coal, grains, iron ore, and more—across the country’s vast rail and road network. The company operates three main segments: Network (which covers the regulated coal rail infrastructure in Queensland), Coal (for coal haulage), and Bulk (for diversified freight, recently boosted by the acquisition of One Rail). With over 2,600km of essential rail track under a 99-year lease, Aurizon sits at the heart of Australia’s commodity supply chain.

A few things jump out from the numbers:

• Market cap sits at $6.31 billion, making Aurizon a sizeable player on the ASX.
• Its dividend yield of 6.08% stands comfortably above the market average, and franking sits at 90%—a real plus for Aussie investors chasing after those valuable franking credits.
• The company’s latest reported earnings per share is $0.211, supporting a dividend per share of $0.23, and giving a P/E ratio of 17.91.

Recent dividend history shows Aurizon paying semi-annual dividends, with franking levels mostly between 60% and 100%. This track record of regular payments, plus relatively high franking, gives some comfort to investors seeking steady, tax-effective income.

The case for Atlas Arteria

Atlas Arteria operates in a different world: international toll roads. The business was spun out of Macquarie Infrastructure Group and owns interests in five toll roads across France, Germany, and the United States. Its core asset is a substantial stake in APRR, a major French toll road network with long-dated concessions, and it also owns the Dulles Greenway in the US.

On the income front, Atlas Arteria goes big:

• Its market cap is $5.49 billion, slightly smaller than Aurizon.
• The dividend yield—at a mouth-watering 10.31%—is one of the highest on the index right now.
• However, ALX dividends are unfranked, which may make a difference for investors comparing take-home income after tax.
• Earnings per share are $0.077, with a dividend per share of $0.40. The P/E ratio is 50.39—a lot higher than Aurizon’s.

Atlas Arteria has a long-standing history of semi-annual, sizeable cash dividends, but none of its payments are franked. For yield hunters, though, the cash on offer is hard to ignore.

Valuation comparison

Here’s a side-by-side look at the key numbers:

Metric	Aurizon Holdings	Atlas Arteria
Market Cap	$6.31 billion	$5.49 billion
P/E Ratio	17.91	50.39
Dividend Yield	6.08% (90% franked)	10.31% (unfranked)
Dividend per Share	$0.23	$0.40
Earnings per Share	$0.211	$0.077

Note: Atlas Arteria’s reported P/E ratio may be based on a different earnings measure (for example, underlying or forward earnings) than the EPS shown here, which is why these figures may not quite line up mathematically.

Aurizon trades on a much lower P/E and higher EPS, but Atlas Arteria counters with a far higher cash yield—though without franking credits.

Which is the better buy?

If I’m picking between these two giants for a safer, sustainable passive income stream, my vote goes to Aurizon.

Here’s why: Although Atlas Arteria offers a juicier headline yield at over 10%, those dividends are fully unfranked, so the income may end up being less tax efficient for Aussie investors once you factor in personal rates. Meanwhile, Aurizon’s 6.08% yield is nearly all franked—making the take-home cash for Australian taxpayers potentially much higher. Aurizon also sports a lower P/E ratio, suggesting the market isn’t demanding such a sky-high price for its profit.

Atlas Arteria’s impressive dividend looks tempting, but that P/E is elevated relative to Aurizon. Without multi-year earnings trend data here, it’s tough to dig deeper, but the numbers nudge me toward Aurizon as the more balanced, reliable passive income play in this match-up.

The post Aurizon Holdings vs Atlas Arteria: Which ASX 200 high-yield share wins for reliable passive income? appeared first on The Motley Fool Australia.

More reading

• 3 great ASX dividend shares with 7%+ yields
• How much is needed in superannuation to target $2,000 a week in passive income
• If I invest $15,000 in Atlas Arteria shares, how much would I get in dividends?
• Here are the top 10 ASX 200 shares today
• Atlas Arteria flags French tax hikes may impact toll road revenues

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

There are plenty of ASX shares that could deliver strong growth over the next few years.

But I particularly like businesses that have already built something successful and still have plenty of room to expand.

Here are three ASX growth shares I would be happy to buy today and hold for many years.

Breville Group Ltd (ASX: BRG)

Breville is one of my favourite examples of an Australian business that has successfully taken its products to the world. The company has built a reputation in premium kitchen appliances, particularly coffee machines.

What I like is how Breville has positioned itself in a market where customers are often willing to spend more for better equipment.

Making coffee at home has become a serious hobby for many people, and Breville has developed products catering to everyone from beginners to enthusiastic home baristas.

I also think there is considerable potential for Breville to build on its international success. The company already has a presence in major markets, but there are still countries where its brands have room to become more established.

Of course, premium appliances are discretionary purchases, so weaker consumer spending can affect sales. But over the next decade, I think Breville has a realistic opportunity to become a much larger global business.

Xero Ltd (ASX: XRO)

Xero is another ASX growth share I would be comfortable backing for the long term. One thing I particularly like about the accounting software provider is how important its platform becomes to customers once they start using it.

A small business might initially sign up to manage its accounts, but over time it can begin using Xero for invoicing, payroll, payments, and other financial tasks.

Accountants also become familiar with their clients’ systems, making the platform an important part of how businesses manage their finances.

I think that creates valuable customer relationships that can last for years. It also gives Xero opportunities to generate more revenue from customers as they adopt additional services.

The acquisition of Melio is particularly interesting because it strengthens Xero’s payments offering and could help accelerate its expansion in the United States.

There are execution risks and artificial intelligence (AI) could be a threat. But with millions of small businesses around the world still relying on older systems, I think Xero has a substantial market opportunity ahead.

Sigma Healthcare Ltd (ASX: SIG)

My final pick is Sigma Healthcare, which I think could look considerably different by 2035.

The combination of Sigma and Chemist Warehouse has created a business with an extensive pharmacy retail network and substantial pharmaceutical distribution operations.

I am particularly interested in its international ambitions. Chemist Warehouse has already demonstrated that its retail model can work outside Australia, and there could be significant opportunities to build its presence in new markets over time.

Healthcare and pharmacy spending should also benefit from ageing populations and ongoing demand for medicines and related products.

I think this positions Sigma to grow into a much larger company over the next decade.

Foolish takeaway

I would be happy owning all three shares for the long term.

Each has an established business and opportunities to grow well beyond its current size.

For me, the prospect of seeing what these companies could become over the next five to ten years makes them worth buying and holding today.

The post Why these are my favourite ASX growth shares to buy and hold appeared first on The Motley Fool Australia.

More reading

• 9 ASX 200 shares experts are backing for growth amid market weakness
• I investigated 3 ASX shares that have fallen sharply. Are they bargains or value traps?
• Droneshield vs Xero: Which ASX tech stock is the better buy for a young growth investor?
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Xero, Ansell, Wesfarmers shares

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It is easy, with a long-term investment like superannuation, to “set and forget” and just assume it’s working as it should.

It is a dangerous trap to fall into, however, and the impact can be large.

Compound interest impacts can be large

Some superannuation funds are perennial underperformers, and if you’re stuck in one of those, you’ll be leaving a lot on the table.

As an example, just a 0.5% difference in performance can have a large effect.

If you invest $100,000 for 20 years at a 5% rate of return, you’ll end up with $265,330.

But if you add just 0.5% to that rate of return, you end up with $291,776 over the same period.

So how do you perform your own superannuation health check?

The easiest way to do this is to use the Federal Government’s YourSuper comparison tool, which can be found on the Australian Taxation Office website.

As the website explains:

The YourSuper comparison tool helps you compare super funds based on their performance. You can access a personalised version or a non-personalised version of the tool. The advantage of using the personalised version via myGov is we show you what your existing super accounts are and you can compare those with others in the tool.

The comparison tool displays a table of MySuper products which are ranked by net returns, updated quarterly, as well as the fees charged by funds.

MySuper products are the default investment option that people are placed into if they don’t choose their own investment option when setting up a fund.

The comparison tool allows you to select up to four superannuation products at a time and will show you the past net returns for three, five, and 10 years, the investment strategy, and the total annual fees.

Check the details of your investments

Beyond confirming that your superannuation fund is performing adequately, it’s also worth assessing whether your investment settings are suitable.

Most funds offer options such as balanced, growth, and high growth, which may be more or less appropriate depending on your risk tolerance, age, and the outlook for the global economy.

The guidance of a financial planner can be helpful in deciding which setting is right for you.

And finally, it’s always good to ensure you are not running more than one superannuation fund at one time, and thereby paying management fees on each.

It’s easy, particularly while young, to accrue more than one fund, but a simple search of your myGov account can tell you whether you have more than one fund in operation, and they’re fairly easy to roll into one. 

The post Is your superannuation fund any good? How to compare performance and fees appeared first on The Motley Fool Australia.

More reading

• If I could only buy 5 ASX shares for retirement, these would make my shortlist
• Here’s the average superannuation balance at 60 and 70 in Australia
• Why the Paladin Energy share price “doesn’t make sense”
• ANZ vs Westpac shares: Which big four bank is the better buy for $5,000?
• Why I’d invest $5,000 into these Betashares ETFs

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.